Armata’s AP-SA02 Wins QIDP Designation, Gains Five-Year Market Exclusivity
FDA grants QIDP designation for AP-SA02 as intravenous adjunct therapy for complicated bacteremia from MSSA and MRSA, securing five-year market exclusivity. Designation also provides eligibility for Fast Track, priority and rolling review as Armata plans a Phase 3 superiority trial in H2 2026.
1. QIDP Designation Details
The FDA has granted Qualified Infectious Disease Product designation to AP-SA02 for intravenous adjunct treatment of complicated bacteremia caused by methicillin-sensitive and methicillin-resistant Staphylococcus aureus. This status secures an additional five years of Hatch-Waxman market exclusivity under the GAIN Act for the multi-phage candidate.
2. Regulatory Incentives and Next Steps
With QIDP status, AP-SA02 becomes eligible for Fast Track designation, enabling more frequent FDA interactions as well as priority and rolling review of its Biologics License Application. Armata intends to submit its Fast Track request promptly and initiate a Phase 3 superiority study in the second half of 2026.
3. AP-SA02 Clinical Background
AP-SA02 is a fixed multi-phage cocktail that demonstrated safety and efficacy signals in a Phase 1b/2a randomized, double-blind, placebo-controlled trial of complicated S. aureus bacteremia. The development was supported by a $26.2 million Department of Defense award, positioning the asset as a late-stage therapeutic candidate in Armata’s bacteriophage pipeline.